Association between Empagliflozin Use and Electrocardiographic Changes

Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use in patients with diabetes mellitus. We compared ECG features of 101 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Antwi-Amoabeng, Daniel, Sathappan, Sunil, Beutler, Bryce D., Ulanja, Mark B., Awad, Munadel, Gullapalli, Nageshwara, Duncan, Phillip, Gbadebo, T. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326746/
https://www.ncbi.nlm.nih.gov/pubmed/35892445
http://dx.doi.org/10.3390/clinpract12040059
Descripción
Sumario:Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use in patients with diabetes mellitus. We compared ECG features of 101 patients before and after initiation of empagliflozin and found that empagliflozin was associated with a significant increase in QRS duration among diabetes patients with heart failure.

Ejemplares similares